LONDON, UK / ACCESSWIRE / September 1, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) ("Ionis"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=IONS. The Company announced on August 30, 2017, that it has earned a $40 million milestone payment from Biogen Inc., (NASDAQ: BIIB) associated with the pricing of SPINRAZA (nusinersen) in Japan. SPINRAZA was approved by the Pharmaceuticals and Medical Devices Agency in Japan, in June 2017, for the treatment of individuals with infantile-onset spinal muscular atrophy (SMA). Currently, Ionis has earned more than $435 million from Biogen for SPINRAZA. For immediate access to our complimentary reports, including today's coverage, register for free now at:
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on IONS and BIIB. Go directly to your stock of interest and access today's free coverage at:
The Company stated that Biogen is working to expand access to SPINRAZA with Marketing Authorization Application (MAA) being reviewed in Switzerland, Israel, South Korea, and Australia, with several other MAAs down the development pipeline. Ionis believes that the speed and breadth at which SPINRAZA has achieved marketing approval across geographies is a recognition of the immense value SPINRAZA may deliver to patients.
Biogen initially licensed the global rights to develop, manufacture, and commercialize SPINRAZA from Ionis in August 2016, and is now responsible for all development, regulatory, and commercialization activities and costs for SPINRAZA, which was initially approved by the US FDA on December 23, 2016, within three months of the regulatory filing.
SPINRAZA is an antisense oligonucleotide (ASO) leveraging Ionis' proprietary antisense technology and is designed to treat Spinal Muscular Atrophy (SMA) caused by mutations or deletions in the SMN1 gene located in chromosome 5q that leads to SMN protein deficiency. SPINRAZA changes the splicing of SMN2 pre-mRNA so as to increase production of full-length SMN protein. Through the use of this technology, SPINRAZA holds the potential to increase the amount of full-length SMN protein in individuals with SMA. Administered through intrathecal injection, which delivers therapies directly to the cerebrospinal fluid around the spinal cord, to maintain the levels of SMN protein, else which would led to the degeneration of motor neurons due to insufficient levels of the protein.
Spinal Muscular Atrophy
SMA is signified by the loss of motor neurons in the spinal cord, and lower brain stem, resulting in progressive and severe muscular atrophy and weakness. SMA of the most severe type can eventually lead the individuals to become paralyzed and have difficulty performing the basic functions of life, like breathing and swallowing. Owing to a defect in the SMN1 gene, people with SMA are unable to produce enough survival motor neuron protein, which is yet again critical for the maintenance of motor neurons.
Company Growth Prospects
Ionis is the leading RNA-targeted drug discovery and development focused on the development of drugs for patients who have the highest unmet medical needs, such as patients with severe and rare diseases. The Company leverages its antisense technology, through which it has created a vast pipeline of first-in-class or best-in-class drug, with over three dozen drugs in development.
Recently, on August 24, 2017, Ionis announced that it had received notice of an unsolicited mini-tender offer by TRC Capital Corp. of Ontario, Canada, to purchase up to 2.5 million shares of Ionis' common stock at a price of $44.88 per share in cash. The offer price of $44.88 per share according to the Company was about 4.47% lower than the $46.98 closing share price of Ionis' common stock on August 18, 2017, the business day prior to the date of the offer. Ionis did not endorse TRC Capital's offer and recommended shareholders not to tender their shares in response to the offer from TRC Capital.
Last Close Stock Review
On Thursday, August 31, 2017, the stock closed the trading session at $53.62, jumping 5.16% from its previous closing price of $50.99. A total volume of 1.22 million shares have exchanged hands, which was higher than the 3-month average volume of 1.20 million shares. Ionis Pharma's stock price skyrocketed 5.59% in the last one month, 8.63% in the past three months, and 80.84% in the previous twelve months. Furthermore, since the start of the year, shares of the Company have surged 12.11%. The stock is trading at a PE ratio of 255.33 and currently has a market cap of $6.87 billion.
Biogen's share price finished yesterday's trading session at $316.56, rising 4.22%. A total volume of 2.50 million shares have exchanged hands, which was higher than the 3-month average volume of 1.40 million shares. The Company's stock price surged 23.34% in the last three months, 6.28% in the past six months, and 12.45% in the previous twelve months. Additionally, the stock rallied 21.19% since the start of the year. Shares of the Company have a PE ratio of 20.79 and currently have a market cap of $67.02 billion.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily